Mazdutide: research
A weekly dual-hormone injection approved in China, with phase 3 weight-loss results.
Also called: IBI362, IBI-362, LY3305677, LY-3305677, Xinermei.
GLP-1 / glucagon dual agonists · GLP-1 and glucagon receptor dual agonist · Evidence: Approved drug.
China-approved. 45 distinct registered human protocols plus one case report found. Planned studies are included; a master-protocol duplicate and nonspecific registry are excluded.
Studies
- First doses (ADA 2021). rct, n=47, Healthy adults. A small single-dose study supported weekly development. (source)
- Early repeat dosing. rct, n=54, Healthy adults. Conference-only results leave important dose and safety details missing. (source)
- Early diabetes dosing. rct, n=24, Adults with type 2 diabetes. Conference-only results leave important dose and safety details missing. (source)
- Early obesity trial. rct, n=36, Chinese adults with overweight plus a complication, or obesity. Weight or glucose improved; stomach symptoms limited tolerability. (source)
- Early diabetes trial. rct, n=42, Chinese adults with type 2 diabetes, with/without metformin. Weight or glucose improved; stomach symptoms limited tolerability. (source)
- Early 9 mg cohort. rct, n=12, Chinese adults with overweight or obesity. Weight or glucose improved; stomach symptoms limited tolerability. (source)
- Early 10 mg cohort. rct, n=12, Chinese adults with overweight or obesity. Weight or glucose improved; stomach symptoms limited tolerability. (source)
- Early US 16 mg trial. rct, n=32, Adults with overweight or obesity, without diabetes. High doses produced weight loss, with frequent stomach symptoms. (source)
- Phase 2 obesity. rct, n=248, Chinese adults with overweight plus hyperphagia/complications, or obesity. Weight or glucose improved; stomach symptoms limited tolerability. (source)
- Phase 2 diabetes. rct, n=250, Chinese adults with type 2 diabetes; diet/exercise with or without metformin. Weight or glucose improved; stomach symptoms limited tolerability. (source)
- Phase 2 obesity: 9 mg. rct, n=80, Chinese adults with BMI ≥30, without diabetes. The 9 mg cohort showed weight loss, with frequent stomach symptoms. (source)
- GLORY-1. rct, n=610, Chinese adults with overweight/obesity. Weight or glucose improved; stomach symptoms limited tolerability. (source)
- DREAMS-1. rct, n=320, Chinese adults with type 2 diabetes; diet/exercise alone. Weight or glucose improved; stomach symptoms limited tolerability. (source)
- DREAMS-2. rct, n=731, Chinese adults with type 2 diabetes; background oral diabetes medicines. Weight or glucose improved; stomach symptoms limited tolerability. (source)
- GLORY-2. rct, n=461, Chinese adults with BMI ≥30; 16.1% had type 2 diabetes. Weight or glucose improved; stomach symptoms limited tolerability. (source)
- US phase 2 obesity. rct, n=179, US adults aged 18–75 with obesity/overweight, without diabetes. Weight or glucose improved; stomach symptoms limited tolerability. (source)
- US phase 2: registry results. rct, n=179, Same participants as US phase 2; not a separate trial. Registry results add 48-week values using the registry analysis. (source)
- DREAMS-3: semaglutide comparison. rct, n=349, Chinese adults with early type 2 diabetes and BMI ≥28. Conference results favored mazdutide over semaglutide 1 mg. (source)
- One adolescent case. case-report, n=1, One 15-year-old boy with obesity, diabetes and high uric acid. One combined-treatment case cannot establish safety or a pediatric dosing standard. (source)
- Liquid versus powder exposure. rct, n=24, Overweight/Obesity. A registered study; efficacy and harms cannot be inferred without results. (source)
- Kidney impairment and exposure. open-label, n=20, Renal Impairment. A registered study; efficacy and harms cannot be inferred without results. (source)
- Warfarin and other oral drugs. pk-study, n=48, Overweight Subjects; Obese Subjects. A registered study; efficacy and harms cannot be inferred without results. (source)
- PCOS (phase 1/phase 2). open-label, n=43, Polycystic Ovary Syndrome. A registered study; efficacy and harms cannot be inferred without results. (source)
- Adolescent dose finding. rct, n=36, Adolescents With Obesity. A registered study; efficacy and harms cannot be inferred without results. (source)
- Alcohol use disorder. rct, n=308, Alcohol Use Disorder. A registered study; efficacy and harms cannot be inferred without results. (source)
- Obesity with heart failure. rct, n=141, Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF); Heart Failure With Mildly Reduced Ejection Fraction. A registered study; efficacy and harms cannot be inferred without results. (source)
- GLORY-MASLD: semaglutide comparison. rct, n=479, Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD). A registered study; efficacy and harms cannot be inferred without results. (source)
- GLORY-OSA: sleep apnea. rct, n=260, Sleep Apnea; Obstructive; Obesity. A registered study; efficacy and harms cannot be inferred without results. (source)
- MASH dose-finding trial. rct, n=181, Metabolic Dysfunction-associated Steatohepatitis (MASH). A registered study; efficacy and harms cannot be inferred without results. (source)
- 15 mg and every-two-week dosing (phase 1/phase 2). rct, n=98, Obesity. A registered study; efficacy and harms cannot be inferred without results. (source)
- LIGHT-COG: diabetes and memory. rct, n=420, Dementia, Mild; Mild Cognitive Impairment; Type 2 Diabetes. A registered study; efficacy and harms cannot be inferred without results. (source)
- After sleeve gastrectomy. rct, n=256, Severe Obesity. A registered study; efficacy and harms cannot be inferred without results. (source)
- Adolescent phase 3. rct, n=180, Adolescents With Obesity or Overweight With Weight-Related Comorbidities. A registered study; efficacy and harms cannot be inferred without results. (source)
- HDM1005 active comparison. rct, n=912, Type 2 Diabetes. A registered study; efficacy and harms cannot be inferred without results. (source)
- GLORY-H: high blood pressure. rct, n=336, Overweight; Obesity; Hypertensive. A registered study; efficacy and harms cannot be inferred without results. (source)
- ASCEND-1: weight maintenance. rct, n=420, Obesity; Weight Control. A registered study; efficacy and harms cannot be inferred without results. (source)
- GLP-1 medicines after surgery. open-label, n=200, Obesity. A registered study; efficacy and harms cannot be inferred without results. (source)
- DREAM-PRE: prediabetes. rct, n=150, Prediabetes; Impaired Fasting Glucose; Impaired Glucose Tolerance (Prediabetes). A registered study; efficacy and harms cannot be inferred without results. (source)
- Coronary plaque. rct, n=116, Obesity & Overweight; Coronary Heart Disease. A registered study; efficacy and harms cannot be inferred without results. (source)
- Switching in diabetes with liver fat. rct, n=72, Type 2 Diabetes Mellitus (T2DM); Nonalcoholic Fatty Liver Disease (NAFLD) With History of Diabetes Melitus. A registered study; efficacy and harms cannot be inferred without results. (source)
- PRIME: living liver donors. rct, n=60, Metabolic Dysfunction-Associated Steatohepatitis; Hepatic Steatosis; Living Liver Donors. A registered study; efficacy and harms cannot be inferred without results. (source)
- IBI3040 active comparison. rct, n=96, Healthy Participants; Overweight or Obese Participants. A registered study; efficacy and harms cannot be inferred without results. (source)
- Diabetes remission trial. rct, n=249, Diabetes Mellitus, Type 2. A registered study; efficacy and harms cannot be inferred without results. (source)
- QUARTET-DKD: kidney combinations. rct, n=820, Type 2 Diabetic Kidney Disease. A registered study; efficacy and harms cannot be inferred without results. (source)
- Endometrial disease combination. rct, n=128, Obesity; Overweight; Atypical Endometrial Hyperplasia; Endometrial Carcinoma Stage I; Endometrioid Endometrial Cancer. A registered study; efficacy and harms cannot be inferred without results. (source)
- Cirrhosis and portal pressure. open-label, n=50, Cirrhosis; Portal Hypertension; Fatty Liver Disease; GLP-1. A registered study; efficacy and harms cannot be inferred without results. (source)
- Fatty pancreas. rct, n=194, Fatty Pancreas; Overweight; Obesity. A registered study; efficacy and harms cannot be inferred without results. (source)
- IBI3046 combination. rct, n=128, Obesity and Overweight. A registered study; efficacy and harms cannot be inferred without results. (source)
- Gout with obesity. open-label, n=30, Gout; Obesity (BMI>30); Hyperuricemia; Metabolic Syndrome. A registered study; efficacy and harms cannot be inferred without results. (source)
- HRS-4729 active comparison. rct, n=240, Type 2 Diabetes. A registered study; efficacy and harms cannot be inferred without results. (source)
- Mazdutide meta-analysis. meta-analysis, n=2292, Participants from earlier trials. This analysis reuses earlier participants; it adds no new dose arm. (source)
- Obesity meta-analysis. meta-analysis, Participants from earlier trials. This analysis reuses earlier participants; it adds no new dose arm. (source)
- Earlier mazdutide synthesis. meta-analysis, Participants from earlier trials. This analysis reuses earlier participants; it adds no new dose arm. (source)
- Dual-agonist class meta-analysis. meta-analysis, Adults in 19 RCTs of four GLP-1/glucagon drugs. Class pooling cannot rank individual drugs or prove long-term safety. (source)
- Mouse liver-fat mechanisms. animal, Mouse models of fatty liver. Animal liver effects are not evidence for a human liver-disease protocol. (source)
- Mouse diabetes and cognition. animal, Diabetic mouse models. No human cognitive benefit is established by this experiment. (source)
Mazdutide dosage
Typical reported dose: 2 mg once a week to start, up to 6 mg
- Early single 5 mg: 5 mg single dose single dose, under the skin. Studied in a trial. Studied in: Healthy adults. (source)
- Early obesity trial: 3 mg: 1 mg once weekly, then 2 mg once weekly, then 3 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Chinese adults with overweight plus a complication, or obesity. (source)
- Early obesity trial: 4.5 mg: 1.5 mg once weekly, then 3 mg once weekly, then 4.5 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Chinese adults with overweight plus a complication, or obesity. (source)
- Early obesity trial: 6 mg: 2 mg once weekly, then 4 mg once weekly, then 6 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Chinese adults with overweight plus a complication, or obesity. (source)
- Early diabetes trial: 3 mg: 1 mg once weekly, then 2 mg once weekly, then 3 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Chinese adults with type 2 diabetes, with/without metformin. (source)
- Early diabetes trial: 4.5 mg: 1.5 mg once weekly, then 3 mg once weekly, then 4.5 mg once weekly once weekly, under the skin. Studied in a trial. Studied in: Chinese adults with type 2 diabetes, with/without metformin. (source)
Highest studied: Highest published weekly SC target found: 16 mg..
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Mazdutide side effects and risks
Reported side effects
- Vomiting: GLORY 2 9 mg: 53.1% vs 1.3% placebo., moderate (source)
- Nausea: GLORY 2 9 mg: 46.9% vs 3.2% placebo., moderate (source)
- Diarrhea: GLORY 2 9 mg: 39.4% vs 6.5% placebo., moderate (source)
- Constipation: Early 16 mg cohorts: 16.7% and 33.3%; placebo: 12.5%., moderate (source)
- Fatigue: Early 16 mg cohorts: 25.0% and 75.0%; placebo: 0%., moderate (source)
- Low blood sugar: Phase 2 diabetes: 10% pooled mazdutide vs 8% placebo., moderate (source)
- Injection site reaction: Phase 2 obesity: 4.8%/1.6%/3.3% at 3/4.5/6 mg; placebo: 6.5%., mild (source)
- Heart rate increase: Observed in early trials; incidence depends on how the event was defined., moderate (source)
- Pancreatitis, severe allergy or dehydration-related kidney injury: Class concerns; available trials cannot establish reliable rare event rates., serious (source)
Stop and get help if
- Severe or persistent belly pain, especially into the back: Stop dosing and get urgent medical assessment.
- Trouble breathing; swelling of lips, tongue or throat: Call emergency services now.
- Chest pain, fainting or a sustained racing heart: Seek emergency care.
- Sudden vision loss or a major vision change: Seek urgent eye/emergency assessment.
- Confusion, seizure or low blood sugar that does not resolve: Call emergency services; do not take another dose.
- Repeated vomiting, inability to keep fluids down or very little urine: Get urgent care for dehydration or kidney injury.
- Belly swelling with vomiting and inability to pass stool or gas: Seek urgent medical assessment.
- Fever or spreading redness, heat or swelling after an injection: Get urgent medical care for possible infection.
Who should avoid it
- pregnant: Excluded from trials; no established pregnancy safety.
- breastfeeding: No established infant safety; avoid exposure while breastfeeding.
- tryingToConceive: Plan stopping and contraception with a clinician; no verified compound-specific washout is given here.
- under18: Pediatric safety and dosing remain limited.
- mtcOrMen2: Personal/family medullary thyroid cancer or MEN2 was excluded. Human thyroid-cancer risk is not established.
- eatingDisorderHistory: Appetite suppression may worsen restrictive eating; this is a precautionary screen.
- pancreatitisHistory: Review prior pancreatitis before exposure; this is also a GLP-1 class precaution.
- gallbladderDisease: Gallbladder symptoms need review during substantial weight loss.
- gastroparesis: Delayed stomach emptying can worsen severe stomach-motility problems.
- diabeticRetinopathy: Rapid glucose improvement can worsen existing eye disease; direct long-term risk is uncertain.
- kidneyDisease: Vomiting and diarrhea can cause dehydration and kidney injury. Special-population data are incomplete.
- liverDisease: Advanced liver disease needs specialist review; trial findings do not establish self-dosing.
- heartCondition: Heart rate rose in early trials; review rhythm problems and symptoms.
- uncontrolledBloodPressure: Review uncontrolled pressure before use; blood pressure changes and dehydration need monitoring.
- surgeryPlanned: Tell the anesthesia team about use; delayed stomach emptying can raise aspiration risk.
- other: Prior severe reaction to this compound or its ingredients should stop re-exposure.
- testedAthlete: No named 2026 prohibition found. China approval changes the S0 analysis; confirm with the anti-doping authority.
Interactions
- Insulin: Additive low-glucose risk; insulin doses may need clinician adjustment.
- Sulfonylureas: Additive low-glucose risk; review dose and glucose checks.
- Other GLP-1 or related appetite injections: Overlapping actions may worsen stomach symptoms and dehydration. No verified home stack has a tested dose.
- Narrow-window oral medicines: Slower stomach emptying or vomiting may alter exposure. Monitoring needs are medicine-specific.
- Oral contraception: Vomiting may reduce pill reliability. A tirzepatide-specific backup rule cannot be assumed for this drug.
- Oral anticoagulants: Illness and poor intake may change anticoagulation. No direct interaction magnitude is established here.
Product quality risks
- No independent published assay series of online mazdutide products was found.
- Indirect evidence: online semaglutide samples had 7%–14% purity and 29%–39% excess content; one had elevated endotoxin.
- FDA names this compound in warnings about unapproved research-labeled GLP-1 products of unknown quality.
- Wrong identity, wrong amount, contamination and counterfeit packaging are separate risks.
How Mazdutide works
The GLP-1 signal helps reduce appetite and control blood sugar. The glucagon signal changes how the liver uses fuel. Animal work suggests higher energy use; its added effect in people is still being measured.
- GLP-1 receptor: Supports fullness and glucose-dependent insulin release; can slow stomach emptying.
- Glucagon receptor: Changes liver fuel handling; may add energy use beyond appetite reduction.
Half-life: 194 hours geometric mean in one small phase 1 trial; range 149–272 hours. Other regimens may differ.
Gaps: Long-term cardiovascular outcomes, rare harms and weight regain after stopping remain uncertain. Chinese product instructions, validated home mixing/storage and independent online-product assay series were not recovered. Several early trial schedules and DREAMS per-arm safety tables were unavailable; no numbers were reconstructed. The high-dose phase 2 abstract has an invalid registry ID; study-family linkage is an inference explained in notes.md. Renal and oral-drug interaction studies are registered, but usable published results were not found. Community prevalence is not measurable from this small, selected sample; reliable cycling and daily dosing reports were not found.
Related to Mazdutide
- Survodutide: A weekly dual-hormone injection with phase 3 weight-loss data and frequent stomach side effects.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA · FDA · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- The Prohibited List, World Anti-Doping Agency · World Anti-Doping Agency · 2026
- Understanding your responsibilities when importing, compounding and supplying unapproved peptide products, Therapeutic Goods Administration · Therapeutic Goods Administration · 2026
- WEGOVY- semaglutide injection, solution WEGOVY- semaglutide tablet, DailyMed · DailyMed · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society., Mozaffarian D et al. · The American journal of clinical nutrition · 2025
- Weight loss medicine Mazdutide approved for commercialization in China, Shanghai Municipal Government · Shanghai Municipal Government · 2025
- Australian Register of Therapeutic Goods (ARTG), Therapeutic Goods Administration · TGA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.